Business Overview
Stemtech Corporation is a global network marketing company that develops and markets science-based stem cell nutrition products under brands including RCM System, stemrelease3, StemFlo, MigraStem, and OraStem, with recent product introductions including Cellect One Shield HOCL skincare in January 2025. The company operates through thirteen subsidiaries internationally and markets products through independent distributors. For the three months ended March 31, 2026, the company is focused on executing its business plan to increase revenue and reduce expenditures while managing substantial operating losses and negative working capital.
Segment Performance
The company does not break out segment performance by business unit in the provided MD&A section. Consolidated revenue for Q1 2026 was $462,957 compared to $868,046 in Q1 2025, representing a 47% decline. Gross profit declined from $720,264 to $353,653 (51% decrease). Operating loss improved slightly from $(1,204,905) to $(1,094,249). Net loss for Q1 2026 was $(1,252,880) compared to $(1,458,726) in Q1 2025.
Forward Guidance
The company states it "will continue to require substantial funds to implement its new investment acquisition plans" and that "The Company s ability to continue as a going concern for the next twelve months from the issuance of these consolidated financial statements depends on its ability to execute its business plan, increase revenue, and reduce expenditures." The company notes it "has reduced its labor force, cut out significant overhead and increased sales in attempts to address the above." The company disclaims reliance on forward-looking statements and notes "Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements."
Key Risk Factors
The company faces substantial doubt regarding its ability to continue as a going concern, with an accumulated deficit of approximately $36 million and working capital deficiency of $10.5 million at March 31, 2026. The company has experienced recurring net losses and negative cash flows from operations since inception and depends on securing additional financing through private placements, preferred stock offerings, or debt issuances to fund operations. Regulatory developments in cannabis laws across jurisdictions present uncertainty, as does the company's ability to achieve market acceptance of its products, compete effectively, and maintain intellectual property protection in what is described as a start-up nature business.
